WOKINGHAM, England--(BUSINESS WIRE)-- On May 31, 2024, Ferguson plc (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"). It is available on the SEC's website at sec.gov and on the SEC Filings page of the Company's website at corporate.ferguson.com/investor/financial-information/sec-filings. In accordance with Listing Rule 14.3.6, copies of resolutions constituting non-ordinary business conducted at the 2024 Special Meeting... (continue reading...)
BASINGSTOKE, England--(BUSINESS WIRE)-- A new study by Juniper Research, the foremost experts in fintech markets, found the number of cards issued by modern card issuing platforms will double from 748 million in 2024 to 1.4 billion in 2029. Modern card issuing platforms are API driven; enabling issuers to issue payment cards instantly. To stay competitive against agile digital-only banks, traditional banks must adopt modern card issuing platforms to respond to... (continue reading...)
AMSTERDAM--(BUSINESS WIRE)-- AM Best analytical staff will discuss challenging conditions that have affected European insurance carriers at a market briefing taking place in Amsterdam on 3 July, 2024.
During AM Best’s Insurance Market Briefing – Amsterdam, members of the analytics team will present their insights and opinions on emerging issues including the global reinsurance landscape, investment trends in the U.S. and European markets, dealing with the... (continue reading...)
MUNICH--(BUSINESS WIRE)-- During 3-5 June, Igloo Coolers will showcase the ICF electric compressor cooler series and IE thermoelectric cooler collection for the first time in the Europe, Middle East and Africa (EMEA) market at Outdoor by ISPO, exhibition area A3 Booth 315. Part of the Dometic Group AB (STO: DOM), Igloo is a U.S.-based brand with a 75+ year history of bringing innovative cooling products to market. In addition to its new active cooling product lines,... (continue reading...)
The new facility in Bleiswijk, Netherlands offers a comprehensive range of cold and ultra-cold services enabling global clinical trial innovation and biorepository storage solutions
BLEISWIJK, Netherlands--(BUSINESS WIRE)--
Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced... (continue reading...)
More Business Wire
View Older Stories-
Discover® Global Network Study Shows 85% of Consumers are Less Likely to Interact with a Business Due to a Poor Payment Experience
-
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
-
Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors
-
Axway Announces the Signing of Binding Agreements for the Acquisition of Sopra Banking Software
-
Sopra Steria: A Significant Milestone Achieved in the Group’s Strategy to Refocus Its Activities on Digital Services and Solutions
-
“MOURI Tech” Expands Global Footprint with Acquisition of “Versant Systems”, Strengthening Presence in APAC Region
-
GenSight Biologics Appoints William Monteith to its Board of Directors
-
Avanzanite Bioscience Reports AKANTIOR® Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries
-
Triumph Motorcycle Dealers Ranked First in Industry Study for Providing Quick and Easy Service Appointments
-
Appointment of Director to Woodside Board
-
Nissan Demonstrates Autonomous-Drive Mobility Services Progress on Public Roads
-
WEBTOON Entertainment Announces Public Filing of Registration Statement for Proposed Initial Public Offering
-
Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
-
New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse
-
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
-
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated
-
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
-
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
-
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
-
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
-
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
-
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
-
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
-
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the Unit
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lin
-
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
-
June Joy at Juicy Stakes Casino
-
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
-
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
-
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
-
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
-
Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
-
AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
-
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
-
Generation Mining Files Final Base Shelf Prospectus and Updates Shareholders
-
Tikehau Capital: Disclosure of shares repurchases from 24 May 2024 to 30 May 2024
-
Government Regulation Creates Blue Oceans
